Literature DB >> 2948218

Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome.

N R Cutler.   

Abstract

Brain metabolism has been measured with positron emission tomography and 18[F] fluoro-2-deoxyglucose. Brain metabolic function remains age invariant in healthy aged subjects 21 to 83 years. Brain metabolism remains unchanged in the mild-moderate severity Alzheimer's disease group and significantly reduced throughout the brain in the late-severe form. Serial assessments over 2 1/2 years of brain metabolic function in an Alzheimer's disease subject with positron emission tomography and 18[F]-fluoro-2-deoxyglucose revealed initial reductions in the parietal lobe and regions prior to neuropsychological changes. Marked elevations in brain metabolism were found in young adult Down syndrome subjects while age-related declines were found in the middle aged (non-demented) Down syndrome subjects and further reductions in the demented Down syndrome individuals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2948218     DOI: 10.1016/0278-5846(86)90010-2

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  9 in total

1.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.

Authors:  Jia Yao; Ronald W Irwin; Liqin Zhao; Jon Nilsen; Ryan T Hamilton; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

Review 2.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

Review 3.  Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope.

Authors:  Showkat Ul Nabi; Andleeb Khan; Ehraz Mehmood Siddiqui; Muneeb U Rehman; Saeed Alshahrani; Azher Arafah; Sidharth Mehan; Rana M Alsaffar; Athanasios Alexiou; Bairong Shen
Journal:  Oxid Med Cell Longev       Date:  2022-05-14       Impact factor: 7.310

Review 4.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

5.  Alzheimer's Disease in Down Syndrome.

Authors:  Elizabeth Head; David Powell; Brian T Gold; Frederick A Schmitt
Journal:  Eur J Neurodegener Dis       Date:  2012-12

Review 6.  Biological Hallmarks of Cancer in Alzheimer's Disease.

Authors:  Kelly N H Nudelman; Brenna C McDonald; Debomoy K Lahiri; Andrew J Saykin
Journal:  Mol Neurobiol       Date:  2019-04-16       Impact factor: 5.590

Review 7.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

Review 8.  The Role of Bioenergetics in Neurodegeneration.

Authors:  Taylor A Strope; Cole J Birky; Heather M Wilkins
Journal:  Int J Mol Sci       Date:  2022-08-16       Impact factor: 6.208

Review 9.  A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia.

Authors:  Funmi Deinde; Jay Kotecha; Lilian Suh Lih Lau; Sagnik Bhattacharyya; Latha Velayudhan
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.